Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 5/2018

01-11-2018 | Original Article

Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy

Authors: Negin Farshchian, Avisa Alavi, Sahel Heydarheydari, Nasrin Moradian

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2018

Login to get access

Abstract

Objective

One of the complications of chemotherapy is peripheral neuropathy. Various studies have shown that potent norepinephrine and serotonin reuptake inhibitors such as gabapentin, venlafaxine and duloxetine have therapeutic effects on neuropathy. The aim of this study was to compare the effects of venlafaxine vs. duloxetine on chemotherapy-induced peripheral neuropathy.

Methods

In this clinical trial, cancer patients who were suffering from chemotherapy-induced peripheral neuropathy comprised the study population. They were randomly assigned to three pharmacotherapy groups including venlafaxine, duloxetine and placebo. Cranial, sensory, motor neuropathies as well as neuropathic pain were evaluated on day 1, week 2, and week 4 after enrollment.

Results

Grade of cranial, motor, sensory and neuropathic pain decreased significantly in venlafaxine and duloxetine groups. This reduction was more considerable in duloxetine group compared to venlafaxine group (P < 0.05).

Conclusion

Duloxetine seems to be more effective than venlafaxine in decreasing the symptoms of chemotherapy-induced peripheral neuropathy. Duloxetine was more effective than venlafaxine in decreasing motor neuropathy and neuropathic pain grade.
Literature
1.
Holley SK (2000) Evaluating patients’ distress from cancer related fatigue: an instrument development study. Oncol Nurs Forum 27(9):1425–1430PubMed
2.
Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419–437CrossRef
3.
Zhang X, Chen WW, Huang WJ (2017) Chemotherapy-induced peripheral neuropathy. Biomed Rep 6(3):267–271CrossRef
4.
Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81(6):772–781CrossRef
5.
Iop A, Manfredi AM, Bonura S (2004) Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol 15(5):712–720CrossRef
6.
Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP (2014) Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 6:135–147CrossRef
7.
Branda RF, Naud SJ, Brooks EM, Chen Z, Muss H (2004) Effect of vitamin B12, folate, and dietary supplements on breast carcinoma chemotherapy–induced mucositis and neutropenia. Cancer 101(5):1058–1064CrossRef
8.
Farquhar-Smith P (2011) Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care 5(1):1–7CrossRef
9.
Biedrzycki BA (2010) Peripheral neuropathy. In: Brown CG (ed) A guide to oncology symptom management. Oncology Nursing Society, Pittsburgh, pp. 405–421
10.
Aziz MT, Good BL, Lowe DK (2014) Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. Ann Pharmacother 48(5):626–632CrossRef
11.
Rowbotham MC, Goli V, Kunz NR, Lei D (2004). Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110(3):697–706CrossRef
12.
Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25(6):871–880CrossRef
13.
Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90(3):377–387CrossRef
14.
Bril V, England JD, Franklin GM et al (2011) Evidence-based guideline: treatment of painful diabetic neuropathy—report of the American association of neuromuscular and electrodiagnostic medicine, the American academy of neurology, and the American academy of physical medicine & rehabilitation. Muscle Nerve 43(6):910–917CrossRef
15.
Dyck PJ (2005) Peripheral neuropathy. Elsevier Inc., Amsterdam
16.
Kautio AL. Chemotherapy-induced neuropathy: prevention and treatment. Helsinki.2012
17.
Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–1367CrossRef
18.
Esin E, Yalcin S (2014) Neuropathic cancer pain: what we are dealing with? How to manage it? OncoTargets Ther 7:599–618
19.
Piccolo J, Kolesar JM (2014) Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am J Health Syst Pharm 71(1):19–25CrossRef
20.
Shahid A, Wilkinson K, Marcu S, Shapiro CM (2011) Brief pain inventory (BPI). InSTOP, THAT and one hundred other sleep scales. Springer, New York. pp 81–88
21.
Sheehan DV, Harnett-Sheehan K, Raj BA (1996) The measurement of disability. ‎Int Clin Psychopharmacol 11:89–95CrossRef
22.
Simão DA, Murad M, Martins C, Fernandes VC, Captein KM, Teixeira AL (2015) Chemotherapy-induced peripheral neuropathy: review for clinical practice. Revista Dor 16(3):215–220CrossRef
23.
24.
Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Lin CC, Yen CC, Tzeng CH (2012) Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer 20(7):1491–1497CrossRef
Metadata
Title
Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy
Authors
Negin Farshchian
Avisa Alavi
Sahel Heydarheydari
Nasrin Moradian
Publication date
01-11-2018
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 5/2018
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-018-3664-y

Other articles of this Issue 5/2018

Cancer Chemotherapy and Pharmacology 5/2018 Go to the issue

Correction

Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models

Clinical Trial Report

A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects

Original Article

Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre

Short Communication

A comparison of the quality of informed consent for phase I oncology trials over a 30-year period

Original Article

Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma

Original Article

A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits